Tuesday 5 November 2024

The Pharma Letter Podcast — Episode 21 — Will radical new EU regs hobble industry?

Pharmaceutical
Simon Wentworth
31 March 2023
podcast-21-big

More on this story...

Biotechnology
European regulator enhances warning on JAK blocker safety
31 March 2023
Biotechnology
Europe follows USA in approving Sotyktu
28 March 2023
Biotechnology
New challenges to navigate to reach regulatory approval, report finds
5 April 2023
Pharmaceutical
European regulatory shake-up fails to impress, as expected
26 April 2023


More ones to watch >


Today's issue

PharmaMar gets $10 million milestone from Janssen for Yondelis
Pharmaceutical
PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Pharmaceutical
Photocure’s Hexvix wins Chinese approval
5 November 2024
Pharmaceutical
Vertex ups guidance again as results exceed estimates
5 November 2024
Biotechnology
Transgene and ProBioGen join forces on cancer vaccines
5 November 2024
Biotechnology
Nxera Pharma and Antiverse partner on GPCRs
5 November 2024
Pharmaceutical
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024
Pharmaceutical
Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
4 November 2024

Company Spotlight

A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.




More Features in Pharmaceutical

PharmaMar gets $10 million milestone from Janssen for Yondelis
5 November 2024
Photocure’s Hexvix wins Chinese approval
5 November 2024
Vertex ups guidance again as results exceed estimates
5 November 2024
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia
5 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze